Skip to main content
. 2023 Jun 4;37(6):531–544. doi: 10.1007/s40263-023-01013-8
Adverse event (AE) profiles for antiseizure medications differ between modes of action and between single substances with the same molecular target.
Perampanel is an AMPA receptor antagonist that is associated with an unfavorable AE profile.
Topiramate, valproate, and zonisamide therapy are associated with an unfavorable AE profile.
Brivaracetam produces fewer psychobehavioral AEs than levetiracetam.
Voltage-gated sodium channel( modulators such as dibenzazepines, lamotrigine, and lacosamide have favorable AE profiles.